Cohort profile The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry

Gilbert Habib; Patrizio Lancellotti; Paola-Anna Erba; Anita Sadeghpour; Marwa Meshaal; Antonia Sambola; Shumaila Furnaz; Rodolfo Citro; Julien Ternacle; Erwan Donal; Bernard Cosyns; Bogdan Popescu; Bernard Iung; Bernard Prendergast; Cécile Laroche; Pilar Tornos; Michal Pazdernik; Aldo Maggioni; Chris P Gale; European Endocarditis (EURO-ENDO) Investigators; Yehia Saleh

doi:10.1093/ehjqcco/qcz018

Back

Journal article

Peer reviewed

Cohort profile The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry

Gilbert Habib, Patrizio Lancellotti, Paola-Anna Erba, Anita Sadeghpour, Marwa Meshaal, Antonia Sambola, Shumaila Furnaz, Rodolfo Citro, Julien Ternacle, Erwan Donal, …

European heart journal. Quality of care & clinical outcomes, Vol.5(3), pp.202-207

04/08/2019

DOI: 10.1093/ehjqcco/qcz018

PMID: 30957862

View Online

Abstract

Aims - The European Society of cardiology (ESC) EURObservational Research Programme (EORP) European Endocarditis (EURO-ENDO) registry aims to study the care and outcomes of patients diagnosed with infective endocarditis and compare findings with recommendations from the 2015 ESC Clinical Practice Guidelines for the management of infective endocarditis and data from the 2001 Euro Heart Survey. Methods and results - Patients (n = 3116) aged over 18 years with a diagnosis of infective endocarditis based on the ESC 2015 infective endocarditis diagnostic criteria were prospectively identified between January 1st, 2016 and March 31st, 2018. Individual patient data were collected across 156 centres and 40 countries. The primary end-point is all-cause mortality in hospital and at 1-year. Secondary end-points are 1-year morbidity (all-cause hospitalisation, any cardiac surgery and infective endocarditis relapse), the clinical, epidemiological, microbiological, and therapeutic characteristics of patients, the number and timing of non-invasive imaging techniques, and adherence to recommendations as stated in the 2015 ESC Clinical Practice Guidelines for the management of infective endocarditis. Conclusion - EURO-ENDO is an international registry of care and outcomes of patients hospitalised with infective endocarditis which will provide insights into the contemporary profile and management of patients with this challenging disease.

Bioengineering

Life Sciences

Details

Title: Subtitle: Cohort profile The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry
Creators: Gilbert Habib - Hôpital de la Timone
Patrizio Lancellotti - University of Liège
Paola-Anna Erba - University of Groningen
Anita Sadeghpour - Shaheed Rajaei Cardiovascular Medical and Research Center
Marwa Meshaal - Cairo University hospitals
Antonia Sambola - Vall d'Hebron Hospital Universitari
Shumaila Furnaz - National Institute of Cardiovascular Diseases
Rodolfo Citro - Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona
Julien Ternacle - Hôpitaux Universitaires Henri-Mondor
Erwan Donal - Université de Rennes
Bernard Cosyns - Universitair Ziekenhuis Brussel
Bogdan Popescu - Ecolab (United Kingdom)
Bernard Iung - Hôpital Bichat-Claude-Bernard
Bernard Prendergast
Cécile Laroche - European Society of Cardiology
Pilar Tornos - Vall d'Hebron Hospital Universitari
Michal Pazdernik - Institute of Clinical and Experimental Medicine
Aldo Maggioni - European Society of Cardiology
Chris P Gale - University of Leeds
European Endocarditis (EURO-ENDO) Investigators
Yehia Saleh (Contributor) - Internal Medicine
Resource Type: Journal article
Publication Details: European heart journal. Quality of care & clinical outcomes, Vol.5(3), pp.202-207
DOI: 10.1093/ehjqcco/qcz018
PMID: 30957862
NLM abbreviation: Eur Heart J Qual Care Clin Outcomes
ISSN: 2058-5225
eISSN: 2058-1742
Publisher: Oxford University Press; OXFORD
Grant note: Abbott Vascular Int.Amgen CardiovascularAstraZenecaBayer AGBoehringer IngelheimBoston ScientificBristol Myers SquibbDaiichi Sankyo Europe GmbHAlliance Daiichi Sankyo Europe GmbHEli Lilly and CompanyEdwardsGedeon Richter Plc.Menarini Int. Op.MSD-Merck Co.Novartis Pharma AGResMedSanofiSERVIERViforPfizer Alliance
This work was supported by Abbott Vascular Int. (2011-2014), Amgen Cardiovascular (2009-2018), AstraZeneca (2014-2020), Bayer AG (2009-2018), Boehringer Ingelheim (2009-2019), Boston Scientific (2009-2012), The Bristol Myers Squibb and Pfizer Alliance (2011-2019), Daiichi Sankyo Europe GmbH (2011-2020), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014-2017), Edwards (20162019), Gedeon Richter Plc. (2014-2016), Menarini Int. Op. (2009-2012), MSD-Merck & Co. (2011-2014), Novartis Pharma AG (2014-2020), ResMed (2014-2016), Sanofi (2009-2011), SERVIER (2009-2018), Vifor (2019-2022).
Language: English
Date published: 04/08/2019
Academic Unit: Internal Medicine
Record Identifier: 9984755384902771

Metrics

9 Record Views

69 Times Cited - Web of Science

See more details